# Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen

> **NCT06456892** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 82 (estimated)

## Conditions studied

- Rhabdomyosarcoma
- Pediatric Cancer

## Interventions

- **DRUG:** Pucotenlimab

## Key facts

- **NCT ID:** NCT06456892
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-06
- **Primary completion:** 2026-06-06
- **Final completion:** 2026-12-06
- **Target enrollment:** 82 (ESTIMATED)
- **Last updated:** 2024-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456892

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456892, "Effectiveness of Pucotenlimab Combined With Standard Chemotherapy Regimen". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06456892. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*